title: Adverse Reaction to Omalizumab in Patients with Chronic Urticaria: Flare Up or Ineffectiveness?
abstract: Omalizumab is a recombinant humanized anti-Ig E monoclonal antibody used as the third line treatment of chronic spontaneous urticaria (CSU). We report four patients with severe antihistamine-resistant CSU, who developed angioedema, anaphylaxis and/or flare up of urticaria at different times following omalizumab therapy.
authors.affiliation: Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey.
authors.forename: Ragıp
authors.initials: R
authors.lastname: Ertaş
authors.affiliation: Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey.
authors.forename: Kemal
authors.initials: K
authors.lastname: Özyurt
authors.affiliation: Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey.
authors.forename: Sinem
authors.initials: S
authors.lastname: Yıldız
authors.affiliation: Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey.
authors.forename: Yılmaz
authors.initials: Y
authors.lastname: Ulaş
authors.affiliation: Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey.
authors.forename: Abdullah
authors.initials: A
authors.lastname: Turasan
authors.affiliation: Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey.
authors.forename: Atıl
authors.initials: A
authors.lastname: Avcı
mesh_terms: D000328:Adult; D000368:Aged; D000707:Anaphylaxis / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D000799:Angioedema / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D002908:Chronic Disease; D004342:Drug Hypersensitivity / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab / Q000009:adverse effects*; D013997:Time Factors; D016896:Treatment Outcome; D014581:Urticaria / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D007155:Immunologic Factors; D000069444:Omalizumab
keywords: Chronic urticaria, Omalizumab, Adverse reaction